Vermont Medicaid

Budget Information

What We Do

Who We Serve

How We Impact

Measures

ACS-MY

AAB: Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis - Age 18-64 (ACS-MY)

PM

MY 2023

44.1%

2

8%

ACS-MY

AMM: Antidepressant Medication Management Acute Phase - Age 18+ (ACS-MY)

PM

MY 2023

78.7%

1

21%

ACS-MY

AMM: Antidepressant Medication Management Continuation Phase - Age 18+ (ACS-MY)

PM

MY 2023

63.8%

2

36%

ACS-MY

AMR: Asthma Medication Ratio - Age 19-64 (ACS-MY)

PM

MY 2023

54.7%

2

0%

ACS-MY

BCS: Breast Cancer Screening - Age 50-74 (ACS-MY)

PM

MY 2023

51.0%

2

-9%

ACS-MY

CBP: Controlling High Blood Pressure - Age 18+ (ACS-MY)

PM

MY 2023

58.4%

3

17%

ACS-MY

CCP: Contraceptive Care for Postpartum Women; MMEC 3 days - Age 21-44 (ACS-MY)

PM

MY 2023

15.4%

2

10%

ACS-MY

CCP: Contraceptive Care for Postpartum Women; MMEC 90 days - Age 21-44 (ACS-MY)

PM

MY 2023

54.0%

3

74%

ACS-MY

CCP: Contraceptive Care for Postpartum Women; LARC 3 days - Age 21-44 (ACS-MY)

PM

MY 2023

2.5%

1

-51%

ACS-MY

CCP: Contraceptive Care for Postpartum Women; LARC 90 days - Age 21-44 (ACS-MY)

PM

MY 2023

19.1%

1

12%

ACS-MY

CCS: Cervical Cancer Screening - Age 21-64 (ACS-MY)

PM

MY 2023

50.0%

1

-4%

ACS-MY

CCW: Contraceptive Care for All Women; MMEC - Age 21-44 (ACS-MY)

PM

MY 2023

25.0%

1

41%

ACS-MY

CCW: Contraceptive Care for All Women; LARC - Age 21-44 (ACS-MY)

PM

MY 2023

5.1%

2

-43%

ACS-MY

CDF: Screening for Depression and Follow Up Plan - Age 18+ (ACS-MY)

PM

MY 2023

0.1%

0

0%

ACS-MY

CHL: Chlamydia Screening in Women - Age 21-24 (ACS-MY)

PM

MY 2023

55.4%

1

-2%

ACS-MY

COB: Concurrent Use of Opioids and Benzodiazepines - Age 18+ (ACS-MY)

PM

MY 2023

16.9%

1

11%

ACS-MY

COL: Colorectal Cancer Screening - Age 46-75 (ACS-MY)

PM

MY 2023

31.0%

1

9%

ACS-MY

FUA: Follow Up After ED Visit for Alcohol or Other Drug Dependence within 30 Days - Age 18+ (ACS-MY)

PM

MY 2023

57.3%

1

19%

ACS-MY

FUA: Follow Up After ED Visit for Alcohol or Other Drug Dependence within 7 Days - Age 18+ (ACS-MY)

PM

MY 2023

37.0%

1

17%

ACS-MY

FUH: Follow Up After Hospitalization for Mental Illness within 30 Days - Age 18+ (ACS-MY)

PM

MY 2023

65.2%

2

-13%

ACS-MY

FUH: Follow Up After Hospitalization for Mental Illness within 7 Days - Age 18+ (ACS-MY)

PM

MY 2023

45.9%

2

-23%

ACS-MY

FUM: Follow Up After ED Visit for Mental Illness within 30 Days - Age 18+ (ACS-MY)

PM

MY 2023

71.4%

1

-8%

ACS-MY

FUM: Follow Up After ED Visit for Mental Illness within 7 Days - Age 18+ (ACS-MY)

PM

MY 2023

61.7%

1

-1%

ACS-MY

FVA: Flu Vaccinations for Adults Age 18-64 (ACS-MY)

PM

MY 2023

32.3%

1

-33%

ACS-MY

HBD: Hemoglobin A1c Control for Patients with Diabetes in Control (<8.0%) - Age 18-75 (ACS-MY)

PM

MY 2023

46.2%

1

1%

ACS-MY

HBD: Hemoglobin A1c Control for Patients with Diabetes in Poor Control (>9.0%) - Age 18-75 (ACS-MY)

PM

MY 2023

44.5%

1

-7%

ACS-MY

HPCMI: Diabetes Care for People with Serious Mental Illness: Hemoglobin A1c (HbA1c) Poor Control (>9%) (ACS-MY)

PM

MY 2023

47.0%

1

-5%

ACS-MY

IET: Initiation of Alcohol & Other Drug Dependence Treatment - Age 18+ (ACS-MY)

PM

MY 2023

41.0%

1

-3%

ACS-MY

IET: Engagement of Alcohol & Other Drug Dependence Treatment - Age 18+ (ACS-MY)

PM

MY 2023

19.9%

1

35%

HP CAHPS

MSC: Medical Assistance with Smoking and Tobacco Use Cessation: Percentage of survey respondents who indicate that they smoke cigarettes or use tobacco products every day or some days

PM

MY 2023

23.3%

3

-46%

HP CAHPS

MSC: Medical Assistance with Smoking & Tobacco Use Cessation: Advising to Quit

PM

MY 2023

74.6%

1

-3%

HP CAHPS

MSC: Medical Assistance with Smoking & Tobacco Use Cessation: Discussing Cessation Medications

PM

MY 2023

54.8%

3

-11%

HP CAHPS

MSC: Medical Assistance with Smoking & Tobacco Use Cessation: Discussing Cessation Strategies

PM

MY 2023

47.8%

2

-9%

ACS-MY

OHD: Use of Opioids at High Dosage - Age 18+ (ACS-MY)

PM

MY 2022

10.8%

3

-19%

ACS-MY

OUD: Use of Pharmacotherapy for Opioid Use Disorder - Age 18-64 (ACS-MY)

PM

MY 2023

90.9%

1

1%

ACS-MY

PCR: Plan All-Cause Readmissions Rate - Age 18-64 (ACS-MY)

PM

MY 2023

9.7%

1

-21%

ACS-MY

PPC: Postpartum Care Rate (ACS-MY)

PM

MY 2023

80.3%

1

23%

ACS-MY

PQI-01: Diabetes Short Term Complications Admission Rate - Age 18+ (ACS-MY)

PM

MY 2023

10.2

2

3%

ACS-MY

PQI-05: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate - Age 40+ (ACS-MY)

PM

MY 2023

17.6

1

-24%

ACS-MY

PQI-08: Heart Failure Admission Rate - Age 18+ (ACS-MY)

PM

MY 2023

10.9

1

213%

ACS-MY

PQI-15: Asthma in Younger Adults Admission Rate - Age18-39 (ACS-MY)

PM

MY 2023

1.3

1

-73%

ACS-MY

SAA: Adherence to Antipsychotics for Individuals with Schizophrenia - Age 18+ (ACS-MY)

PM

MY 2023

81.0%

1

51%

ACS-MY

SSD: Diabetes Scrng for People w/ Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications - Age 18-64 (ACS-MY)

PM

MY 2023

76.3%

3

12%

Clear Impact Suite is an easy-to-use, web-based software platform that helps your staff collaborate with external stakeholders and community partners by utilizing the combination of data collection, performance reporting, and program planning.